ERBB2 and neoplasm: In previous studies, retargeting of NK‐92 cells to cancer cells derived from solid tumours with a Her‐2/neu‐specific CAR resulted in efficient lysis of otherwise NK‐resistant, ErbB2/HER2‐expressing target cells in vitro, and enhanced tumour localization and anti‐tumoural activity in vivo26, 27.